Jane Street Group LLC Makes New Investment in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX)

Jane Street Group LLC bought a new stake in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 25,837 shares of the specialty pharmaceutical company’s stock, valued at approximately $96,000. Jane Street Group LLC owned about 0.20% of Eagle Pharmaceuticals at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in EGRX. Perceptive Advisors LLC bought a new position in shares of Eagle Pharmaceuticals in the second quarter valued at approximately $971,000. Jacobs Levy Equity Management Inc. bought a new position in Eagle Pharmaceuticals in the 3rd quarter valued at $453,000. Cubist Systematic Strategies LLC purchased a new stake in shares of Eagle Pharmaceuticals during the 2nd quarter valued at $145,000. XTX Topco Ltd bought a new stake in shares of Eagle Pharmaceuticals during the 2nd quarter worth $113,000. Finally, Creative Planning purchased a new position in shares of Eagle Pharmaceuticals in the 3rd quarter worth about $59,000. 85.36% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, StockNews.com initiated coverage on shares of Eagle Pharmaceuticals in a research report on Wednesday, January 8th. They issued a “hold” rating on the stock.

Eagle Pharmaceuticals Trading Up 16.1 %

Eagle Pharmaceuticals stock opened at $0.65 on Wednesday. The business’s 50 day simple moving average is $0.69 and its 200 day simple moving average is $2.63. Eagle Pharmaceuticals, Inc. has a 12 month low of $0.00 and a 12 month high of $6.81.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.